Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy

Acta Haematol. 2010;124(3):153-9. doi: 10.1159/000320173. Epub 2010 Oct 11.

Authors

Thomas Schroeder¹, Fabian Zohren, Christian Saure, Ingmar Bruns, Akos Czibere, Nelli Nancy Safaian, Roland Fenk, Rainer Haas, Guido Kobbe

Affiliation

¹ University of Duesseldorf, Medical Faculty, Department of Haematology, Oncology and Clinical Immunology, Duesseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de

PMID: 20938170
DOI: 10.1159/000320173

No abstract available

MeSH terms

Adult
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Benzenesulfonates / administration & dosage
Benzenesulfonates / adverse effects
Benzenesulfonates / therapeutic use*
Enzyme Activation / genetics
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / enzymology
Leukemia, Myeloid, Acute / genetics*
Male
Middle Aged
Mutation*
Niacinamide / analogs & derivatives
Phenylurea Compounds
Pyridines / administration & dosage
Pyridines / adverse effects
Pyridines / therapeutic use*
Retrospective Studies
Sorafenib
Treatment Outcome
Young Adult
fms-Like Tyrosine Kinase 3 / genetics*
fms-Like Tyrosine Kinase 3 / metabolism

Substances

Antineoplastic Agents
Benzenesulfonates
Phenylurea Compounds
Pyridines
Niacinamide
Sorafenib
FLT3 protein, human
fms-Like Tyrosine Kinase 3